January 27, 2016 MPR
A recently published case study details the first known incidence of
sulfa hypersensitivity in primary HIV. The findings could be significant
as they may provide clinical evidence to support the correlation
between viral load and adverse drug reactions (ADRs) to
trimethoprim-sulfamethoxazole (TMP-SMX) without a severe decrease in CD4
count. The study also sheds new light on how an adverse reaction to
sulfa drugs may aid in early diagnosis of HIV.
The study focuses on a 55-year-old African-American male who
presented with a diffuse maculopapular rash and difficulty breathing due
to an adverse reaction while being treated with TMP-SMX. Three days
prior to presenting, he had incision drainage and TMP-SMX therapy for a
gluteal fold abscess. The patient denied any IV drug use, sexual
relations with men, or high-risk sexual behavior. His initial exam
showed mild respiratory distress, severely swollen tongue and lips, and
diffuse perioral cracking with fissures; he was negative for
lymphadenitis and fever. The patient was administered supplemental
oxygen, intramuscular epinephrine, and methylprednisolone for treatment
of suspected anaphylaxis.
The rash progressed to his left buccal mucosa and the base of the
penile shaft. The patient was subsequently tested for potential
infectious etiologies and found to have a positive HIV viral load
consistent with an acute HIV infection. This was confirmed two weeks
later by a 3rd generation test. The patient later admitted to having unprotected sex with two women, two weeks prior to initial presentation.
Conclusion
This case suggests how asymptomatic acute HIV infection may be
identified by an adverse reaction to TMP-SMX. Also demonstrated is
clinical evidence to support the correlation between viral load and ADRs
to TMP-SMX without a severely diminished CD4 count. The authors stress
that the limitations of one study cannot show causality, and therefore
call for further research into whether viral proteins themselves are the
root cause of HIV-related sulfa reactions.
No comments:
Post a Comment